Leucovorin and 5-FU
ApprovedSmall molecule
Leucovorin and 5-FU is one of 66 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Approved.
2
Indications
3
Total Trials
2
Active Trials
65
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Leucovorin and 5-FU
AAkeso
Approved
Eylea
RegeneronPreclinical
Emend IV
Merck & Co.Preclinical
PORTRAZZA
Eli LillyPreclinical
Gas-X
PPortuguese Oncology Institute, Coimbra
Preclinical
Ketalar
AAultman Health Foundation
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Andriol
AAuxilium
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Colorectal Cancer2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Leucovorin and 5-FU. EMBL-EBI & Wellcome Sanger Institute.
- [4]